<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-16 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-16</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-16</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-19ea04696e5479232550cc954cb886b1b0a94c98</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/19ea04696e5479232550cc954cb886b1b0a94c98" target="_blank">Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</a></p>
                <p><strong>Paper Venue:</strong> PLoS ONE</p>
                <p><strong>Paper TL;DR:</strong> The distinct features of driver gene alterations in different subgroups based on histology and smoking status were helpful in defining patients for future clinical trials that target these genes.</p>
                <p><strong>Paper Abstract:</strong> Background Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with specific genetic alterations. We aimed to define subgroups of patients with candidate driver genes in patients with non-small cell lung cancer. Methods Patients with primary lung cancer who underwent clinical genetic tests at Guangdong General Hospital were enrolled. Driver genes were detected by sequencing, high-resolution melt analysis, qPCR, or multiple PCR and RACE methods. Results 524 patients were enrolled in this study, and the differences in driver gene alterations among subgroups were analyzed based on histology and smoking status. In a subgroup of non-smokers with adenocarcinoma, EGFR was the most frequently altered gene, with a mutation rate of 49.8%, followed by EML4-ALK (9.3%), PTEN (9.1%), PIK3CA (5.2%), c-Met (4.8%), KRAS (4.5%), STK11 (2.7%), and BRAF (1.9%). The three most frequently altered genes in a subgroup of smokers with adenocarcinoma were EGFR (22.0%), STK11 (19.0%), and KRAS (12.0%). We only found EGFR (8.0%), c-Met (2.8%), and PIK3CA (2.6%) alterations in the non-smoker with squamous cell carcinoma (SCC) subgroup. PTEN (16.1%), STK11 (8.3%), and PIK3CA (7.2%) were the three most frequently enriched genes in smokers with SCC. DDR2 and FGFR2 only presented in smokers with SCC (4.4% and 2.2%, respectively). Among these four subgroups, the differences in EGFR, KRAS, and PTEN mutations were statistically significant. Conclusion The distinct features of driver gene alterations in different subgroups based on histology and smoking status were helpful in defining patients for future clinical trials that target these genes. This study also suggests that we may consider patients with infrequent alterations of driver genes as having rare or orphan diseases that should be managed with special molecularly targeted therapies.</p>
                <p><strong>Cost:</strong> 0.02</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e16.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e16.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor activating mutations (exon 18-21; e.g. exon 19 deletions, exon 21 L858R, G719 variants, L861R)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Canonical activating mutations in the EGFR tyrosine kinase domain (exons 18-21) observed as frequent drivers in lung adenocarcinoma, including exon 19 deletions and exon 21 L858R among others.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR activating mutations (exon 18 G719A/V/D; exon 19 deletions e.g. E746-A750del; exon 21 L858R/L861R, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations and small in-frame deletions (activating kinase domain mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR (receptor tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>40.3% (140/347 adenocarcinomas); 49.8% (114/229) in non-smoker adenocarcinoma subgroup</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (PCR-based sequencing of EGFR exons 18-21) and clinical literature on EGFR as driver</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper cites established clinical sensitivity to EGFR TKIs for activating EGFR mutations (background literature); no new in vitro functional assays reported in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Enriched in adenocarcinoma and in never-smokers; significantly higher in non-smokers vs smokers (40.9% vs 12.4% overall).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Known predictive biomarker for response to EGFR TKIs (gefitinib/erlotinib) (cited in the paper).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>347 (total adenocarcinoma samples in cohort); EGFR tested in 517 NSCLC samples overall (147 positives).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR-based Sanger sequencing of EGFR exons 18-21</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e16.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR T790M</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR exon 20 T790M mutation (resistance-associated)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>EGFR exon 20 T790M is a secondary kinase-domain mutation associated with acquired resistance to EGFR TKIs; detected among EGFR-mutant cases in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR T790M (exon 20)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (substitution in kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR (receptor tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Observed among EGFR-positive cases; paper reports 11 exon 20 mutations in total EGFR set (out of 147 EGFR+), but not broken down specifically for adenocarcinoma fraction</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (PCR-based sequencing) and cited clinical literature linking T790M to acquired resistance</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper references literature that T790M is a resistance mechanism to EGFR TKIs; no new functional assays in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Associated with acquired resistance to EGFR TKIs (background literature cited).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Implicated in resistance to first-generation EGFR TKIs; clinical relevance noted (literature).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>EGFR sequencing performed in up to 517 NSCLC samples (147 EGFR mutants detected overall); adenocarcinoma total 347.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR-based Sanger sequencing of EGFR exons</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e16.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS (codon 12)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS activating mutations (codon 12 and others; e.g. G12C, G12V, G12D)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Oncogenic RAS mutations concentrated at codon 12 observed in lung adenocarcinoma and enriched in smokers; mutually exclusive with EGFR in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS codon 12 point mutations (e.g. G12C, G12V, G12D and others)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense substitutions at codon 12)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS (RAS pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>7.1% (24/340) in adenocarcinoma overall; higher in smokers with AC (12.0% in smoker AC subgroup; 14/117)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (PCR-based sequencing of KRAS codons 12/13/59/60)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No new functional assays reported here; literature supports KRAS as oncogenic driver.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More frequent in smokers and enriched in adenocarcinoma; mutually exclusive with EGFR in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Not targeted in this study; KRAS mutations are known to confer resistance to EGFR TKIs (cited literature).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Adenocarcinoma samples n=347 (KRAS tested in 340 AC samples per table); overall KRAS tested in 498 samples with 27 positives.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR-based Sanger sequencing (KRAS codons 12,13,59,60)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e16.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF (general)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF mutations (exons 11 and 15)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>BRAF kinase domain mutations detected at low frequency in lung adenocarcinoma (exons 11 and 15), representing infrequent RAF-pathway drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF mutations (exon 11 and exon 15 variants; unspecified amino-acid changes in this paper)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF (RAF pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>2.3% (7/307) in adenocarcinoma (BRAF overall 1.5% (7/452) across tested NSCLC samples)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (high-resolution melting analysis for BRAF exons 11 and 15)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No new functional assays reported; literature indicates BRAF can be oncogenic in cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Observed only in adenocarcinoma in this cohort; two cases co-occurred with EGFR in this study (overlap noted).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potential RAF-pathway target (not directly evaluated here).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Adenocarcinoma samples n=347; BRAF tested in 307 AC samples (7 positive).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>High-resolution DNA melting analysis (exons 11 and 15)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e16.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EML4-ALK fusion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EML4-ALK fusion gene (ALK rearrangement)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Fusion of EML4 and ALK creating a constitutively active kinase fusion oncogene detected in a subset of lung adenocarcinomas, enriched in some non-smoker adenocarcinoma patients.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EML4-ALK gene fusion (ALK rearrangement)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (oncogenic kinase fusion)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK (tyrosine kinase fusion)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>7.7% (10/130) in adenocarcinoma for samples tested; 9.3% (8/86) in non-smoker adenocarcinoma subgroup (denominators vary due to subset testing).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (multiple PCR and RACE on cDNA to detect fusion transcripts); paper cites association with tumors lacking EGFR/KRAS in background/reference</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No new functional work in this study; paper and references recognize ALK fusions as oncogenic drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Enriched in adenocarcinoma and in non-smoker AC subgroup in this cohort; one case co-occurred with EGFR mutation in this study (overlap observed).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Recognized actionable target in literature (ALK inhibitors) â€” paper frames ALK as a candidate target for individualized therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Adenocarcinoma total n=347; ALK tested in 130 AC samples (10 positives); ALK tested in 239 NSCLC overall (15 positives).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Multiple PCR and RACE on cDNA (fusion transcript detection)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e16.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>c-Met amplification</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET (c-Met) gene high-level amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>High-level amplification of the MET proto-oncogene (c-Met) observed at low frequency in lung adenocarcinoma and implicated as a resistance mechanism to EGFR inhibitors in the literature.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>c-Met (MET) high-level gene amplification</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene amplification (copy number increase)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET (receptor tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>4.5% (14/308) in adenocarcinoma (20/448 overall NSCLC tested gave 4.5% overall)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>qPCR-based copy-number assay (qPCR on DNA) for MET amplification; literature linking MET amplification to TKI resistance is cited.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper references MET amplification as a mechanism of acquired EGFR TKI resistance (background literature); no new functional experiments reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected across histologies at low frequency; present in adenocarcinoma and more broadly; overlaps with EGFR mutation occurred in some patients.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Implication as a resistance mechanism to EGFR TKIs and potential target for MET inhibitors (discussed in literature referenced by paper).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Adenocarcinoma n=347; MET copy-number tested in 308 AC samples (14 positives); MET tested in 448 NSCLC samples overall (20 positives).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>qPCR on genomic DNA (copy-number assessment with cutoff mean+5SD of controls)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e16.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PIK3CA (PI3K catalytic subunit) mutations (exons 9 and 20)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mutations in PIK3CA (exon 9 helical domain and exon 20 kinase domain) detected at low frequency in adenocarcinoma, representing activation of the PI3K pathway.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PIK3CA mutations (exon 9 and exon 20; occasional concurrent 9+20)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (activating substitutions in PI3K)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PIK3CA (PI3K pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>4.2% (13/307) in adenocarcinoma (overall PIK3CA 4.4% (20/452) across tested NSCLC samples)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (high-resolution melting analysis for PIK3CA exons 9 and 20)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No functional assays reported in this study; PIK3CA is a recognized oncogene in other literature.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected in adenocarcinoma including non-smoker AC subgroup (5.2% in non-smoker AC).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potential therapeutic target (PI3K pathway inhibitors) suggested as candidate for individualized therapy in literature context; no treatment response data provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Adenocarcinoma n=347; PIK3CA tested in 307 AC samples (13 positives); overall tested in 452 NSCLC samples (20 positives).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>High-resolution DNA melting analysis (exons 9 and 20)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e16.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PTEN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PTEN loss-of-function / mutation (exons 1-9 variants)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Somatic PTEN mutations (various truncating and missense changes) observed at low frequency across NSCLC and in adenocarcinoma; PTEN is a tumor suppressor regulating PI3K signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PTEN mutations (examples reported: C71F, N91K, Q298X, Y68H among others)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations and truncating mutations (loss-of-function alterations)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PTEN (negative regulator of PI3K/AKT pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>7.0% (8/115) in adenocarcinoma (overall NSCLC PTEN 9.5% (21/220) across tested samples)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (PCR-based sequencing of PTEN cDNA/exons 1-9)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No new functional experiments in this paper; PTEN loss is known to activate PI3K/AKT signaling (background knowledge referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>PTEN mutations were more enriched in smokers and in squamous cell carcinoma in this cohort; in adenocarcinoma PTEN seen in non-smoker AC subgroup at 9.1% (7/77 tested).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Impacts PI3K/AKT pathway signalling and may affect response to PI3K pathway inhibitors; specific therapeutic data not provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Adenocarcinoma n=347; PTEN tested in 115 AC samples (8 positives); overall PTEN tested in 220 NSCLC samples (21 positives).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR-based sequencing of PTEN cDNA (exons 1-9)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e16.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>STK11 (LKB1)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>STK11 (LKB1) mutations (exons 1-5 deletions/frameshifts)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor-suppressor STK11 (also LKB1) mutations, including small deletions and truncations, detected at low frequency in lung adenocarcinoma and enriched in smokers in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>STK11 mutations and small deletions (examples: M125-Y126 del, S59 del, S69X, L9-S213 del)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>small deletions, truncating mutations (loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>STK11 (LKB1; tumor suppressor, AMPK pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>8.6% (5/58) in adenocarcinoma for the subset tested (overall STK11 7.9% (8/101) in tested NSCLC subset)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (PCR-based sequencing of STK11 cDNA/exons 1-5)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No new functional assays in this paper; STK11 is discussed as a known tumor suppressor with roles in lung cancer in cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>STK11 mutations were more frequent in smokers and in smoker-AC subgroup (19.0% in smoker AC subgroup but note small denominators).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>May define a biologically distinct subgroup; potential implications for metabolism-targeted approaches discussed but no direct therapeutic data provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Adenocarcinoma n=347; STK11 tested in 58 AC samples (5 positives); overall STK11 tested in 101 NSCLC samples (8 positives).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR-based sequencing of STK11 cDNA (exons 1-5)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e16.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>DDR2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>DDR2 (discoidin domain receptor 2) point mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Rare DDR2 kinase-domain point mutations detected at very low frequency in NSCLC (reported here in smokers with squamous cell carcinoma), representing an emerging actionable RTK alteration in lung cancer (mainly SCC).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>DDR2 point mutations (examples reported: M117V in exon 6; R680L in exon 16)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (kinase/receptor domain substitutions)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>DDR2 (receptor tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>0% in adenocarcinoma in this cohort (DDR2 overall 1.2% (2/166) in tested NSCLC; both DDR2 cases were in smoker SCC subgroup).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (PCR-based sequencing of DDR2 exons)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No functional assays reported in this paper; paper cites literature (reference) identifying DDR2 as therapeutic target in SCC.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Observed only in smokers with SCC in this cohort (4.4% in smoker SCC subgroup); absent in adenocarcinoma here.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Identified in literature as a potential therapeutic target in SCC (paper references other work); no clinical response data in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>DDR2 tested in 166 NSCLC samples; not detected in adenocarcinoma samples tested (0/97 AC).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR-based sequencing of DDR2 exons (exons 6,9,14,16,18 targeted)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e16.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e16.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FGFR2 P303R</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>FGFR2 point mutation (P303R in exon 7)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A single FGFR2 point mutation (P303R) detected at very low frequency in NSCLC (observed in smoker SCC subgroup in this cohort), representing a rare receptor-tyrosine-kinase alteration.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>FGFR2 P303R (exon 7) point mutation</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense in FGFR2)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>FGFR2 (receptor tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>0% in adenocarcinoma in this cohort (FGFR2 overall 0.6% (1/165) in tested NSCLC; the one FGFR2 case was in smoker SCC subgroup).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (PCR-based sequencing of FGFR2 exons 6,7,14)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>No functional evidence provided in this paper; FGFR2 discussed as potential RTK involved in resistance biology in cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected only in smoker SCC subgroup (2.2% in smoker SCC subgroup); absent in adenocarcinoma in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potential target for FGFR inhibitors per broader literature, but no direct data presented here.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>FGFR2 tested in 165 NSCLC samples; no positives in AC (0/96 AC tested).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR-based sequencing of FGFR2 exons</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status', 'publication_date_yy_mm': '2012-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases <em>(Rating: 2)</em></li>
                <li>Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression <em>(Rating: 2)</em></li>
                <li>Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer <em>(Rating: 2)</em></li>
                <li>Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer <em>(Rating: 2)</em></li>
                <li>Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC) <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>